Not sure which GLP 1 drug is right for you? Let’s look at the options available in India.
Evidence based patient guide · 8 min read · By RealMedVision
GLP-1 drugs in India have quickly become one of the most searched health topics in the country. If you or someone in your family has type 2 diabetes or is exploring medical weight management, you’ve probably come across names like Ozempic, Wegovy, Rybelsus and Mounjaro. This guide explains what each one actually does, what it costs in 2026, and what a doctor checks before prescribing it.
Quick Answer
The main GLP-1 drugs in India are Ozempic and Rybelsus (for type 2 diabetes), and Wegovy and Mounjaro (also approved for weight management). Semaglutide generics, available since March 2026, start near ₹1,290 a month; Mounjaro, with no generic yet, starts near ₹14,000. All are prescription-only medicines. The right one depends on your diagnosis, health history and budget, not on which drug is trending online.
What Are GLP-1 Drugs, and Why Do They Matter for India?
GLP-1 stands for glucagon-like peptide-1, a hormone the gut releases after eating. It tells the pancreas to release insulin, tells the liver to hold back on releasing sugar, and tells the brain that the stomach is full. GLP-1 drugs are built to copy this hormone at a stronger, more sustained dose than the body produces on its own. That’s how they lower blood sugar in type 2 diabetes and, for some people, lead to substantial weight loss.
This matters more in India than in most countries. The Indian Council of Medical Research’s ICMR-INDIAB study, the largest national survey of its kind, found that 11.4 percent of adults, or roughly 101 million people, live with diabetes, and another 15.3 percent, about 136 million people, have prediabetes. The same study found generalised obesity in 28.6 percent of adults and abdominal obesity in 39.5 percent[2]. Those numbers are why GLP-1 drugs in India have moved from a niche prescription to one of the fastest-growing categories in Indian pharmacy in under two years. If you are tracking diabetes, our HbA1c normal range chart and blood sugar chart by age can also help you understand the numbers your doctor may discuss.
Source: Anjana RM, et al. Lancet Diabetes Endocrinol. 2023;11(7):474-489.
GLP-1 Drugs in India: Main Medicines Available in 2026
| Medicine | Active ingredient | Form | Main use |
|---|---|---|---|
| Ozempic | Semaglutide | Weekly injection | Type 2 diabetes |
| Wegovy | Semaglutide | Weekly injection | Chronic weight management |
| Rybelsus | Semaglutide | Daily tablet | Type 2 diabetes |
| Mounjaro / Yurpeak | Tirzepatide | Weekly injection | Type 2 diabetes and weight management |
| Generic semaglutide | Semaglutide | Injection or tablet | Product dependent |
Ozempic
Ozempic contains semaglutide and is used for type 2 diabetes. It is given as a once-weekly injection. Some people lose weight while taking it, but that does not mean the product should be used for every type of weight loss.
Wegovy
Wegovy injection price in India is one of the main concerns for patients considering this medicine. Wegovy contains the same molecule as Ozempic but at a higher maintenance dose, and it is the version specifically approved for chronic weight management. It is also sold under a second brand name, Poviztra injection, through Novo Nordisk’s partnership with Emcure Pharma.
There is also growing interest in a possible Wegovy pill in India, especially among people who prefer an oral medicine over a weekly injection.
Rybelsus
Rybelsus is oral semaglutide, taken as a tablet on an empty stomach, at least 30 minutes before food. Because it is swallowed rather than injected, some patients find it easier to start with, though the tablet still needs to be taken correctly every single day to work as intended.
Mounjaro
Mounjaro is tirzepatide, a molecule that activates two gut hormone receptors, GIP and GLP-1, instead of one. For a detailed dose-wise breakdown, see our guide to Mounjaro injection price in India. Cipla also distributes the identical medicine under the brand name Yurpeak.
Generic Semaglutide
Semaglutide’s Indian market changed rapidly after the patent expiry in March 2026. Several Indian manufacturers entered the market with lower cost alternatives. These generics do not automatically replace Ozempic, Wegovy or Rybelsus dose for dose; a doctor still needs to confirm the correct strength and titration schedule.
GLP-1 Drugs in India Prices in 2026
Starting-dose prices only. Costs rise as the dose is increased. Prices change, so verify the current MRP before purchasing.
Diabetes Treatment vs Weight Management: Why the Label Matters
The most common source of confusion is treating every GLP-1 drug as the same product. It is a class of medicines, and each product has its own approved use, dose and treatment plan.
Ozempic and Rybelsus are used for blood sugar control in type 2 diabetes. Wegovy is designed for chronic weight management in eligible patients. Tirzepatide products require their own assessment based on the patient’s diagnosis and treatment goals.
A doctor evaluating someone with type 2 diabetes but a normal body weight is looking at different risks and benefits than a doctor treating someone with obesity but normal blood sugar. Copying a friend’s medicine or changing the dose without guidance can create avoidable risks.
Which One Actually Works Better?
For years, comparisons between these medicines came mainly from separate clinical trials. That made direct comparisons difficult. SURMOUNT-5 was one of the major head-to-head trials comparing tirzepatide with semaglutide in adults with obesity without diabetes.
Over 72 weeks, tirzepatide produced greater average weight loss than semaglutide in that study. The average reduction in body weight was 20.2 percent with tirzepatide compared with 13.7 percent with semaglutide.
Source: SURMOUNT-5. Clinical trial results are group averages and do not predict an individual patient’s result.
That is a group average, not a guarantee for any individual. Individual results can differ because people vary in their response, side effects and ability to continue treatment.
Side Effects: What to Expect
Nausea, vomiting, diarrhoea, constipation and reduced appetite are among the most common side effects of these medicines. Symptoms are often more noticeable when treatment begins or when the dose is increased.
Eating smaller meals, eating slowly and staying hydrated may help some people manage mild digestive symptoms. Persistent vomiting, dehydration or severe abdominal pain should not be ignored.
More serious risks can include pancreatitis, gallbladder problems and low blood sugar when these medicines are combined with insulin or certain other diabetes medicines. Product specific safety information should always be checked before treatment.
Who Needs Extra Caution?
A doctor should review your full medical history before starting a GLP-1 medicine. Extra caution may be needed in people with a history of pancreatitis, gallbladder disease, severe digestive conditions, kidney problems or certain endocrine conditions.
Pregnancy and pregnancy planning also need a direct discussion with a doctor before treatment. Product specific warnings and contraindications can differ.
Buying GLP-1 Drugs in India Safely
These are prescription medicines. Do not buy injectable GLP-1 medicines from social media sellers, messaging groups or websites that do not follow proper prescription requirements.
Buy from a licensed pharmacy or hospital pharmacy. Check the manufacturer’s name, batch number, expiry date and strength before accepting the medicine. If you are comparing injectable diabetes treatments more broadly, our Awiqli insulin price in India guide covers another prescription injectable medicine with a different dosing approach.
Storage is also important. Check the storage instructions on the exact product you receive because requirements can differ between products and after a pen or vial has been opened.
Key Takeaways
- Four branded GLP-1 medicines are sold in India: Ozempic, Wegovy, Rybelsus and Mounjaro, plus more than a dozen generic semaglutide brands since March 2026.
- Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy and Mounjaro are approved for both diabetes-related and weight-related use, depending on the brand.
- Mounjaro has no generic competitor yet, so it remains one of the most expensive options.
- Generic semaglutide injections brought prices down sharply after the March 2026 patent expiry.
- A head-to-head clinical trial found tirzepatide produced more average weight loss than semaglutide, but individual results vary widely.
- These are prescription-only medicines. Buying them without a valid prescription, or from unverified online sellers, carries real safety risk.
The Bottom Line
The GLP-1 market in India looks very different in 2026 than it did two years ago. Mounjaro arrived in 2025, and semaglutide generics entered the market after the patent expired in March 2026. Patients now have more choices, from a ₹1,290 generic injection to a ₹14,000-plus branded tirzepatide pen, but comparing them has also become more confusing. The question that actually matters isn’t “which drug loses the most weight.” It’s which drug fits your diagnosis, your medical history, your budget for however long treatment continues, and your doctor’s read on the risks. That’s not something an article, a price chart or a pharmacy website can decide for you.
Frequently Asked Questions
1. What are the main GLP-1 drugs available in India in 2026?
Ozempic, Wegovy, Rybelsus and Mounjaro (also sold as Yurpeak) are the main branded options, alongside more than a dozen generic semaglutide brands that launched after the March 2026 patent expiry.
2. Is Mounjaro a GLP-1 drug?
Mounjaro’s active ingredient, tirzepatide, activates both the GIP and GLP-1 receptors, so it’s usually grouped with GLP-1 medicines even though it’s technically a dual-receptor drug.
3. Are Ozempic and Wegovy the same medicine?
They share the same active ingredient, semaglutide, but Ozempic is approved for type 2 diabetes and Wegovy for chronic weight management at a different maintenance dose. They aren’t interchangeable without medical guidance.
4. How much do GLP-1 drugs cost in India right now?
Generic semaglutide injections start near ₹1,290 a month. Branded Ozempic and Wegovy start around ₹5,660 a month at the lowest dose. Rybelsus averages about ₹10,000 a month. Mounjaro starts near ₹14,000 a month and rises significantly at higher doses.
5. Does tirzepatide really work better than semaglutide?
In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide over 72 weeks. That’s a group-level finding, not a guarantee for any individual, and it needs to be weighed against tirzepatide’s higher cost.
6. Can Rybelsus replace injectable semaglutide?
Both contain semaglutide, but the tablet and injection have different dosing and absorption profiles. A doctor should decide whether switching between them is appropriate for a specific patient.
7. Are the new generic semaglutide brands safe?
A lower price doesn’t by itself confirm quality. Buy generics only from a licensed pharmacy, and confirm the manufacturer and batch details before use, the same way you would with a branded product.
8. Can I get a GLP-1 medicine without a prescription?
No. These are prescription-only drugs in India. Buying them without a valid prescription is both unsafe and against the law, regardless of what a seller online may claim.
Medically reviewed by
This guide was checked for medical accuracy by our review board before publishing.
Dr. Praveen Verma, MBBS, MD (Pathology)
Pathologist and Clinical Laboratory Specialist.
Dr. Himanshu Morya, MBBS
Medical Educator.
References
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. NEJM
- Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474-489. The Lancet
- Gulf News and Bloomberg. India gets first weight-loss drug as Eli Lilly launches Mounjaro. Gulf News
- Business Standard. As generics wave builds up, Novo Nordisk slashes Ozempic and Wegovy prices. 1 April 2026. Business Standard
- Bloomberg. Generic Ozempic to Launch in India at $14 as Patent Expires for GLP-1 Drugs. 20 March 2026. Bloomberg
- Reuters via MarketScreener. Ozempic launches in India with Novo Nordisk pricing low end at $24 a week. MarketScreener
- Business Standard. New oral diabetes and obesity drug sale doubles in India amid demand surge. 9 May 2024. Business Standard
- NovoCare, Novo Nordisk. RYBELSUS list price and prescribing safety information, including thyroid C-cell tumour warning. NovoCare
- Medkart. Rybelsus 3mg Tablet: contraindications, including MTC and MEN 2 history. Medkart
- CNBC. India is launching cheap weight-loss drugs, but Novo Nordisk is betting its brands will stay on top. 23 March 2026. CNBC